Cargando…
Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer
There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐lacking exon2 (FIRΔexon2), anti‐sorting nexin 15, and anti‐sp...
Autores principales: | Kobayashi, Sohei, Hiwasa, Takaki, Ishige, Takayuki, Kano, Masayuki, Hoshino, Tyuji, Rahmutulla, Bahityar, Seimiya, Masanori, Shimada, Hideaki, Nomura, Fumio, Matsubara, Hisahiro, Matsushita, Kazuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894018/ https://www.ncbi.nlm.nih.gov/pubmed/33306856 http://dx.doi.org/10.1111/cas.14767 |
Ejemplares similares
-
Anti‐FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma
por: Kobayashi, Sohei, et al.
Publicado: (2019) -
Post-transcriptional regulation of BRG1 by FIRΔexon2 in gastric cancer
por: Ailiken, Guzhanuer, et al.
Publicado: (2020) -
Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients
por: Kobayashi, Sohei, et al.
Publicado: (2016) -
Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers
por: Ogura, Yukiko, et al.
Publicado: (2018) -
Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library
por: Kobayashi, Sohei, et al.
Publicado: (2018)